ARO-DIMERPA
Asset
Designed to lower low-density lipoprotein cholesterol and triglycerides.
- Stage
- Phase 1
- Modality
- Oligonucleotide
- Target
- Lipid and ceramide metabolism
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Hyperlipidemia; mixed
Phase 1, Recruiting, NCT07223658, clinicaltrials.gov, 16 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.